The most advanced is ISB 1342, a first-generation bispecific antibody targeting both cluster of differentiation 38 (CD38) on myeloma cells and CD3 on T cells, which is in phase 1 testing for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback